ESG Sustainability Report

Overview

The report records TSH Biopharm's 2024 performance across business growth, materiality, climate, people, and community engagement. Consolidated operating revenue reached NT$1,115,716 thousand, while the company identified 11 material topics through an impact-based assessment. The report also discloses Category 1, Category 2, and Scope 3 greenhouse gas emissions, energy and water use, and solid waste. Social highlights include 72 year-end employees, employee health and DEI initiatives, watershed restoration through pesticide-free Leopard Cat Rice, and support for the Old Five Old Foundation.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 4 August 2025
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services